Presbyopia | Ophthalmology Innovation Source

Exploring Novartis’ Interest in Medtech

Reza Zadno, PhD, EIR at InterWest Partners explains his new role at the Novartis Venture Fund. He’ll advise the pharma company on where to commit its considerable dollars in Medtech. Novartis, which own Alcon, historically has invested in Medtech and has done a nice job investing in companies like Zadno’s Visiogen. Speaking With: Reza Zadno…

MEDICEM

MEDICEM is a group of biomedical companies focusing on research, development and commercialization of medical devices. Our WIOL–CF Bioanalogic Polyfocal IOL, represents new step in evolution of IOLs for the patients with cataract and presbyopia. WIOL-CF offers vision to all distances, including restored reading capability, in all light conditions. www.medicem.com

AcuFocus

AcuFocus is committed “to continuously adapting and expanding” its small aperture technology. The company’s first device, the KAMRA, received US regulatory approval in April 2015, and the firm has begun a slow launch. In development is the IC-8 intraocular lens (IOL). To date, AcuFocus has “extensive clinical data” on about 200 patients. The IC-8 already…

ReVision Optics

The presbyopia market is estimated to comprise more than 2 billion people by 2020. ReVision Optics has developed the Raindrop Near Vision inlay to address that market, with a potential of 30 million eligible patients. The Raindrop itself is a 2-mm diameter hydrogel inlay, 30 microns thick. It’s 80% water. It’s clear, so it enables…

Looking Deep at Extended Depth-of-Focus IOLs

Multifocal IOLs, perhaps the best established solution to the problem of enabling post-cataract patients to see clearly at all distances, work by incorporating discrete refractive optical zones or diffractive echelettes into the lens. Accommodating IOLs, which aim to provide the same benefit, use ciliary muscle power to move the lens and/or change its shape to…

Google Lens Clinical Trials to Start in 2016

Novartis, through its Alcon eye-care division, intends to start clinical trials of an accommodative Google “smart” contact lens in human eyes next year, Novartis Chief Executive Joe Jimenez told the Swiss French-language newspaper Le Temps last week. “This project is progressing well,” Jimenez told Le Temps reporter Willy Boder. “When we announced the agreement a…

A Look at Premium IOLs

Can Accommodating IOLs Fuel Demand? For nearly two decades, “presbyopia-correcting” intraocular lenses (IOLs) have been available to post-cataract surgery patients, but for a variety of reasons they have garnered only modest interest. According to Market Scope, presbyopia-correcting lenses only account for 2.4% of total IOLs implanted globally in 2014. Moreover, use of these IOLs has…

Spotlight on Presbyopia – Market Overview

Participant: Richard Lindstrom, MD Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. View Full Profile

Spotlight on Presbyopia

Participants: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health. View Full Profile Malvina B. Eydelman, MD Dr. Eydelman has been involved in all aspects of assuring the safety and…

ReVision Optics

The Raindrop Near Vision Inlay has had three of the four modules submitted for the IDE, and the fourth is expected to be submitted some time in Q3 2015. Barring any unforeseen issues, that should put it on track for an Ophthalmic Panel discussion some time in the H1 2016, with a likely approval in…

AcuFocus

Nick Tarantino, Chief Global Clinical Research & Regulatory Affairs Officer AcuFocus’ newest technology, the IC-8 small aperture IOL, builds on the company’s long-term experience with small aperture optics (it developed the KAMRA lens for presbyopia about 10 years ago). The IC-8 essentially takes the KAMRA inlay from the corneal plane to the lens plane. The…

PowerVision’s Cheskin Discusses The Potential Of The Company’s Accommodating IOL, FluidVision

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 035″] For 10 years PowerVision has been advancing its accommodating IOL, Flu-idVision. Co-Founder, CEO and President Barry Cheskin explains how the company has kept its focus on someday capturing a huge piece of the IOL market. Podcast Guest Barry Cheskin Barry Cheskin is Co-Founder, President & CEO of PowerVision. Mr. Cheskin…